Evaluation of SPN-812 ER High Dose in Adolescents With ADHD
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 09 Aug 2017 Status changed from planning to not yet recruiting.
- 10 Mar 2017 New trial record
- 28 Feb 2017 According to a Supernus Pharmaceuticals media release, company will initiate this phase III clinical testing during the second half of 2017.